LNO 9
LNO 9 is an orally active LOXL2 inhibitor and NO donor, with an IC50 of 0.17 μM against human LOXL2. LNO 9 competitively binds to the LTQ cofactor of LOXL2 to form an irreversible complex, thereby inhibiting collagen oxidation and abnormal cross-linking. LNO 9 releases nitric oxide (NO) to increase cGMP levels in pulmonary artery smooth muscle cells. LNO 9 inhibits hypoxia-induced collagen modification and possesses vasodilatory activity. LNO 9 ameliorates right ventricular hypertrophy and pulmonary artery medial thickness in rat models induced by hypoxia and Monocrotaline (HY-N0750), and can be used for research on pulmonary hypertension.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 分子式: C23H24F4N4O7
- 分子量:544.45
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
LNO 9 (2 h) exhibits selective inhibition of human LOXL2 over human LOX, LOXL3, SSAO, DAO, MAO-A, and MAO-B, with an LOXL2 IC50 of 0.17 μM[1].
LNO 9 (20-40 μM; 24 h) significantly inhibits hypoxia-induced proliferation of HPASMCs, with efficacy superior to lenumlostat[1].
LNO 9 (20-40 μM; 24 h) significantly inhibits hypoxia-induced migration of HPASMCs, with efficacy superior to lenumlostat[1].
LNO 9 (20-40 μM) modulates sGC, YAP/TAZ, and fibrotic signaling pathways in hypoxia-induced HPASMCs, increasing p-VASP and p-YAP/p-TAZ while reducing PKG1, nuclear YAP/TAZ/TEAD4, α-SMA, collagen I, fibronectin 1, and p-Smad3[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Hypoxia-induced human pulmonary arterial smooth muscle cells (HPASMCs)
-
Concentration:20-40 μM
-
Incubation Time:24 h
-
Result:Significantly suppressed hypoxia-induced HPASMC proliferation, with efficacy superior to lenumlostat at equivalent concentrations.
-
Cell Line:Hypoxia-induced human pulmonary arterial smooth muscle cells (HPASMCs)
-
Concentration:20-40 μM
-
Incubation Time:24 h
-
Result:Significantly suppressed hypoxia-induced HPASMC migration, with greater efficacy than lenumlostat at equivalent concentrations.
LNO 9 (15-30 mg/kg; p.o.; daily; 14 days) significantly reduces RVSP, ameliorates right ventricular hypertrophy, inhibits pulmonary vascular remodeling, and increases survival rate to 60% in monocrotaline (HY-N0750)-induced pulmonary hypertension rats via dual inhibition of LOXL2 and stimulation of sGC[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley rat with pulmonary arterial hypertension (male, 160-180 g, hypoxia-induced modeling)[1]
-
Dosage:15 mg/kg; 30 mg/kg
-
Administration:p.o.; daily; 14 days
-
Result:Reduced right ventricular systolic pressure (RVSP) to 37.8 mmHg (vs. hypoxia model 50.8 mmHg) at 15 mg/kg, and to 29.9 mmHg (vs. hypoxia model 50.8 mmHg) at 30 mg/kg, with greater reduction than lenumlostat 30 mg/kg (43.3 mmHg).
Ameliorated right ventricular hypertrophy via decreased RV/(LV + S) ratio and RV/tibia length ratio, without reducing rat body weight.
Reduced total, soluble, and insoluble collagen content in pulmonary arteries, decreased collagen cross-linking (insoluble/soluble collagen ratio), and reduced pulmonary arterial medial wall thickness (PAMT%).
Increased pulmonary artery p-VASP protein levels and decreased PKG1, α-SMA, and collagen I protein levels compared to the hypoxia group.
化学情報
-
分子量 544.45
-
分子式 C23H24F4N4O7
-
SMILES
NCC1=CC(C(F)(F)F)=NC(OC2=CC(C(N3C[C@H]([C@@H](C3)F)OC(CCCCO[N+]([O-])=O)=O)=O)=CC=C2)=C1
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
LNO 9 関連分類
HY-183644 関連分類
Powered by Bioz